Survival analysis of time to reimbursement of novel medicines in five Eurasian countries

Compared to other global pharmaceutical innovation leaders, China still needs to make further efforts in strengthening public funding reimbursement of novel medicines. A forward-thinking strategy for health technology assessment that provides advanced technical support in conjunction with the regulatory authority to pharmaceutical innovation companies at the early research and development stage is critical for reducing TTR of novel medicines and accelerating patient access. To balance timely patient access and risk control, strategies such as risk-sharing mechanisms for novel medicines with clinical and cost uncertainties, and temporary reimbursement with alternative sources of funding to support real-world evidence collection could be considered.